Wrapping up an inspiring week at European Association of Nuclear Medicine (EANM) 2024! Proud of the Tetrakit team’s contributions to the advancement of nuclear medicine:
“Novel FAPi dimers labeled via tetrazine ligation” – Dr. Marcel Martin presented our latest research using the click chemistry-based TetraKit platform, focusing on radioligand therapy for FAPi dimers.
“Pre-targeting Approach: Moving into Clinical Application, Utopia or Reality?” – Prof. Matthias Herth, our CSO, led a session on the clinical potential of pre-targeting techniques, using tetrazine ligation to enable accurate antibody-based PET imaging across challenging barriers such as the BBB. This advance brings us closer to personalized diagnostics and new possibilities in imaging.
Excited for the future of nuclear medicine! 🚀💡
